The stock of Taro Pharmaceutical Industries Ltd. (NYSE:TARO) hit a new 52-week low and has $102.71 target or 8.00% below today’s $111.64 share price. The 6 months bearish chart indicates high risk for the $4.65B company. The 1-year low was reported on Sep, 30 by Barchart.com. If the $102.71 price target is reached, the company will be worth $372.00M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 537,859 shares traded hands or 137.57% up from the average. Taro Pharmaceutical Industries Ltd. (NYSE:TARO) has declined 20.55% since February 26, 2016 and is downtrending. It has underperformed by 30.98% the S&P500.
Analysts await Taro Pharmaceutical Industries Ltd. (NYSE:TARO) to report earnings on November, 1.
According to Zacks Investment Research, “Taro Pharmaceutical Industries is engaged in the production, research and development, and marketing of prescription and over-the-counter pharmaceutical products, with a focus on generic products. In addition to the production of finished dosage form drugs, they also synthesize the pharmaceutical chemicals used in their production. Products are sold through wholesalers, generic drug distributors, drug store chains, mass merchandisers, HMOs, food stores, pharmacies and hospitals.”
More notable recent Taro Pharmaceutical Industries Ltd. (NYSE:TARO) news were published by: Forbes.com which released: “RSI Alert: Taro Pharmaceutical Industries (TARO) Now Oversold” on August 24, 2016, also Seekingalpha.com with their article: “Taro Pharma: Seeking A Catalyst” published on July 28, 2016, Seekingalpha.com published: “Invest Like Vailshire: Taro Pharmaceutical Industries Ltd Is A Hidden Gem” on September 30, 2015. More interesting news about Taro Pharmaceutical Industries Ltd. (NYSE:TARO) were released by: Seekingalpha.com and their article: “Taro Pharmaceutical Industries’ (TARO) CEO Kal Sundaram on Q4 2016 Results …” published on May 27, 2016 as well as Seekingalpha.com‘s news article titled: “Taro Shareholders Stand To Benefit From Ownership Struggle” with publication date: November 24, 2015.
TARO Company Profile
Taro Pharmaceutical Industries Ltd. (Taro), incorporated on June 3, 1959, is a science pharmaceutical company. The Firm develops, makes and markets prescription (Rx) and over-the-counter (OTC) pharmaceutical products, primarily in the United States, Canada and Israel. Taro also develops and makes active pharmaceutical ingredients (APIs), primarily for use in its finished dosage form products. The Company’s primary areas of focus include semi-solids formulations, such as creams and ointments, and other dosage forms, such as liquids, capsules and tablets, primarily in the dermatological and topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.